
- MONARCC
Trial Status
In Follow-up
Cancer Type
Colorectal Cancer
Protocol Title
A randomised phase 2 study of panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer
Purpose of the Study
The aim of this study is to investigate the activity of anti-EGFR monotherapy, or combined with infusional 5FU, in a molecularly selected, elderly patient population with metastatic colorectal cancer.
Eligibility Criteria
Inclusion Criteria
- Adults aged 70years and over.
- Histologically or cytologically confirmed, previously untreated, metastatic colorectal cancer
- Suitable for panitumumab or panitumumab plus infusional 5FU, as deemed by the investigator.
- No prior chemotherapy.
- Prior palliative radiotherapy is allowed, provided no concurrent chemotherapy was administered.
- Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments.
- Signed, written informed consent.
Exclusion Criteria
- Contraindications to investigational product.
- Any prior treatment with cetuximab or panitumumab or bevacizumab.
- Concurrent toxicity from any prior agent has not resolved to grade 1 or less.
- Any major surgical procedure within two weeks of cycle 1 day 1.
- History of interstitial lung disease or pulmonary fibrosis.
- Any other reason the investigator feels will prevent the patient from complying with the protocol specified treatments and assessments.
- Life expectancy of less than 3 months.
- Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety.
- Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol
Contact Email
Study Chair
Dr Matthew Burge
DETAILED INFORMATION AVAILABLE
Available online at the Australian New Zealand Clinical Trial Registry (ANZCTR) Please click here
Funding
2016 Innovation Fund Grant
Trial Status
In Follow-up
Cancer Type
Colorectal Cancer
Protocol Title
A randomised phase 2 study of panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer
Aim
The aim of this study is to investigate the activity of anti-EGFR monotherapy, or combined with infusional 5FU, in a molecularly selected, elderly patient population with metastatic colorectal cancer.
Background
Metastatic colorectal cancer is a disease of the elderly. Anti-EGFR antibodies have not been well studied in an elderly patient population unsuited to combination chemotherapy. The median age in trials involving these agents is 60-65 years. As a result there is an opportunity to investigate the activity of anti-EGFR monotherapy, or combined with “light” chemotherapy in a molecularly selected, hitherto under-investigated but prevalent patient population.
CLINICAL TRIAL DESIGN
A prospective randomised phase 2 study to assess the activity of panitumumab alone versus panitumumab plus 5FU as first line treatment for RAS wild type elderly patients with metastatic colorectal cancer.
Patients Recruited
Click to access the table and view recruitment data on all AGITG open trials:
Contact Email
monarcc@ctc.usyd.edu.auPrincipal Investigator
Dr Matthew Burge
More Information
More detailed information available online at the Australian New Zealand Clinical Trial Registry (ANZCTR) here
Funding
AGITG Innovation Fund ($100,000)
Alan Bishop Fund ($20,000)